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Abstract
Background: Epidemiological data show that the incidence of carcinomas in humans is highly dependent on age.
However, the initial steps of the age-related molecular oncogenic processes by which the switch towards the
neoplastic state occurs remain poorly understood, mostly due to the absence of powerful models. In a previous
study, we showed that normal human epidermal keratinocytes (NHEKs) spontaneously and systematically escape
from senescence to give rise to pre-neoplastic emerging cells.
Methods: Here, this model was used to analyze the gene expression profile associated with the early steps of
age-related cell transformation. We compared the gene expression profiles of growing or senescent NHEKs to
post-senescent emerging cells. Data analyses were performed by using the linear modeling features of the limma
package, resulting in a two-sided t test or F-test based on moderated statistics. The p-values were adjusted for
multiple testing by controlling the false discovery rate according to Benjamini Hochberg method.
The common gene set resulting of differential gene expression profiles from these two comparisons revealed a
post-senescence neoplastic emergence (PSNE) gene signature of 286 genes.
Results: About half of these genes were already reported as involved in cancer or premalignant skin diseases.
However, bioinformatics analyses did not highlight inside this signature canonical cancer pathways but metabolic
pathways, including in first line the metabolism of xenobiotics by cytochrome P450. In order to validate the
relevance of this signature as a signature of pretransformation by senescence evasion, we invalidated two
components of the metabolism of xenobiotics by cytochrome P450, AKR1C2 and AKR1C3. When performed at the
beginning of the senescence plateau, this invalidation did not alter the senescent state itself but significantly
decreased the frequency of PSNE. Conversely, overexpression of AKR1C2 but not AKR1C3 increased the frequency
of PSNE.
Conclusions: To our knowledge, this study is the first to identify reprogrammation of metabolic pathways in
normal keratinocytes as a potential determinant of the switch from senescence to pre-transformation.
Keywords: Senescence, Neoplastic transformation, Xenobiotics, AKR1Cs, Keratinocytes, Gene expression profile
* Correspondence: olivier.pluquet@ibl.fr
1CNRS, UMR8161, Institut de Biologie de Lille, 1 rue Calmette, 59000 Lille,
France
2Université Lille 1 Sciences et Techniques, 59650 Villeneuve d’Ascq, France
Full list of author information is available at the end of the article
© 2014 Martin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Martin et al. Molecular Cancer 2014, 13:151
http://www.molecular-cancer.com/content/13/1/151
Background
The progression from normal cells to cancer is a multistep
process that requires a wide variety of molecular alter-
ations. To override the normal mechanisms controlling
cellular proliferation, transformed cells accumulate somatic
or inherited mutations in several tumor suppressor genes,
oncogenes and genes that are involved in maintaining
genomic stability [1,2]. Another driving condition of trans-
formation is the chromosomal instability which includes
loss of heterozygosity (LOH), aneuploidy, chromosome
translocation and gene amplifications [3]. In addition, epi-
genetic silencing through DNA methylation has been
shown to strongly affect the activity of tumor suppressor
genes and oncogenes during malignant transformation
[4,5]. Therefore, the phenotype and natural history of
transformed cells is determined by the accumulation of
changes and by the order of events. In all cases, cells are
fully transformed to the neoplastic stage only when they
acquired functional capabilities to survive, proliferate and
disseminate despite genomic instability [6]. It is not yet
clear which immediate pathways program preneoplastic
lesions which then progress to a fully transformed pheno-
type. During the last decade, clinical, epidemiological, ani-
mal and gene expression profiling studies have been used
to identify differentially regulated genes or pathways im-
portant for tumorigenesis. However, when transcriptional
profiling utilizes cell lines, it often involved isogenically
matched non-transformed and transformed cells through
overexpression of telomerase (hTERT) and oncogenes such
as v-Src [7], H-Ras [8]. These approaches make not pos-
sible to kinetically follow initial and intermediate stages be-
tween normal and fully transformed cells. Therefore, the
current clinical models lack initial phases and the current
in vitro culture models lack the importance of the order of
the events.
Aging is associated with a number of events at the
molecular, cellular and physiological levels that influence
malignant transformation. It appears that the incidence
of carcinomas, the most frequent type of cancer in
humans, highly increases with age, unlike to other types
of cancer (NCI cancer statistics). Effects of aging on the
body are accompanied by an increase in senescent cells,
which are viable but have lost their ability to divide [9].
Through its capacity to inhibit cell proliferation, senes-
cence was recognized as a tumor suppressor mechanism
[9]. However, several lines of evidence indicate that it
would also have a tumor promoter role through non-cell
and cell autonomous mechanisms. The senescent fibro-
blasts secrete inflammatory factors that can promote the
proliferation of cancerous cells and the appearance of
tumor clones [10]. In addition, we and others found that
normal human mammary epithelial cells (HMECs) and
normal human epidermal keratinocytes (NHEKs) can
spontaneously escape from the senescent state, emerge
to re-enter the cell cycle and undergo cell divisions
[11,12]. In the case of NHEKs, we named this process
post-senescence neoplastic emergence (PSNE). We dem-
onstrated that clones of small cells emerge from senescent
cells at a frequency between 10−2 to 10−4 by atypic mitosis
but did not come from a pre-existing subpopulation.
Emergent cells showed consistent cellular morphologies
similar to normal growing cells compared to enlarged sen-
escent cells associated with a loss of senescence-associated
β-Gal activity. A Subcutaneous injection of emerging cells
in nude mice induced after several months disseminated
skin lesions (hyperplasia/small carcinomas), strongly sug-
gesting the tumorigenic potential of emerging cells [12].
Characterization of emerging cells showed that they dis-
played normal karyotype [12], did not carry Ras mutation,
did not form colony in soft agar [12] but can become inva-
sive in an inflammatory environment [13]. This indicated
that in culture the post-senescent emergence gave rise to
pre-transformed cells with tumorigenic potential rather
than cells at the fully-transformed neoplastic stage. There-
fore, post-senescence emergence of NHEKs may represent
an early stage in the process of transformation, mimicking
a physiological mode of oncogenic transition in a context
of aging.
In order to gain insights into the molecular basis of early
transformation process, by using microarray transcriptomic
data combined to bioinformatic analyses, we identified a
specific gene expression signature of this pre-transformed
phenotype. This signature comprises in particular genes in-
volved in xenobiotics metabolism including the NADP
(H)-dependent oxidoreductases AKR1C2 and AKR1C3.
Further functional approaches confirmed the involvement
of this new pathway in early steps of cancer initiation in a
context of aging.
Results
Identification of a post-senescence neoplastic emergence
(PSNE) gene expression signature
To establish a gene signature specific of the earliest steps of
tumorigenesis, we performed a transcriptomic analysis of
post-senescent emergent NHEKs in comparison with sen-
escent and young ones. We harvested RNAs from NHEK
cultures at exponential growth phase (Y), senescence plat-
eau (S) or post-senescence emergence (E) (Figure 1A), re-
verse transcribed the RNAs and then hybridized them to
RNG-MRC human set 25K microarrays as described in the
methods section. Comparison between E vs Y and E vs S
were performed with three biological replicates (from the
same donor) and using a dye-swap strategy to limit color
bias. The R package limma was used to test for differential
expression. Variances were modelled using an empirical
Bayesian approach in order to increase the sensitivity of the
experiment and thus mitigate the low number of replicates.
The visual observation of the MAPlots and the shape of
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p-values histograms (Additional file 1: Figure S1A and B)
validate the statistical modelling, warranting further ana-
lyses and interpretation of differentially expressed genes.
For delineating the differentially expressed genes, we ap-
plied as a first filter a range of False Discovery Rate (FDR)
from 0.1 to 1% (Figure 1B). We retained the most stringent
FDR value of 0.1%. As a second filter, we applied log (2)
fold change (E/Y or E/S) ≥ 1.1. Hence, 417 genes differen-
tially expressed between E vs Y and 375 genes between E vs
S were selected. A Venn diagram analysis indicated that
286 genes were common to the two conditions. These 286
genes were all either up-regulated both in E vs Y and E vs S
or down-regulated both in E vs Y and E vs S, suggesting
that they represent the PSNE driver genes (Figure 1C). This
gene set, hereafter called the PSNE signature, is presented
in Additional file 2: Table S1. Validation of the array data
was carried out on a subset of up- and down-regulated
genes by quantitative real-time PCR (Additional file 1:
Figure S2), hence validating the overall signature. The
PSNE signature was then the basis of bioinformatics ana-
lyses. The flow chart of these analyses is depicted in Figure 2.
The PSNE signature is relevant of premalignant states or
established epithelial cancers
In a first step (Figure 2), we wanted to evaluate whether the
PSNE signature was relevant to cancerogenesis. To this
Figure 1 Acquisition of the PSNE gene signature. (A) NHEK growth curve and representative photomicrographs of senescent (S) and
emergent NHEKs (E) as compared to NHEKs in exponential growth phase (Y) observed by phase-contrast microscopy. (B) Number of differentially
up- and down-regulated genes in E versus Y NHEKs and E versus S NHEKs analysed with a range of FDR filters from 1 to 0.1%. (C) Venn diagram
showing the PSNE gene signature defined by the overlap of differentially expressed genes in E vs Y and E vs S NHEKs.
Martin et al. Molecular Cancer 2014, 13:151 Page 3 of 13
http://www.molecular-cancer.com/content/13/1/151
end, we performed an analysis of the over-represented
genes associated to diseases and disorders using Ingenuity
software (Ingenuity Pathway Analysis (IPA), www.ingenuity.
com). This analysis revealed that 36% of the PSNE genes
are annotated in at least one cancer type (Figure 3A) and
this was expanded to 50.7% (145/286 genes) by performing
extensive literature mining. These 145 genes are highlighted
in grey in Additional file 2: Table S1. It is worth to note that
18% of the PSNE genes are involved in psoriasis, a benign
skin disease characterized by hyperproliferation of keratino-
cytes (Figure 3A), directly showing that PSNE can be used
as a model for studying the initial steps of tumorigenesis.
The comparison of the PSNE signature with those of com-
mon cancer types showed that the genes of the PSNE
signature annotated in cancer (50.7%) are preferentially as-
sociated with the most frequent carcinomas, including
colorectal, breast, skin and female genital organs carcin-
omas (Figure 3B), with a range of 4–54 genes (1.4-18.9%)
within each cancer type category (Figure 3B). Finally, to de-
termine whether the PSNE signature is relevant of early
steps of carcinogenesis, and especially of early steps of non-
melanoma skin carcinogenesis (NMSC), we compared by
literature mining the PSNE signature with array-based tran-
scriptional profiles of actinic keratosis (AK) and arsenic-
induced cutaneous hyperplastic lesions, two premalignant
state related models of NMSCs [14-19]. The PSNE gene set
overlaps with a total of 28 genes belonging to one or more
profiles of the aforesaid premalignant models (Figure 3C).
These results suggest that the PSNE gene signature is
relevant to epithelial human cancers and comprises
genes required in pre-malignant states, thereby validat-
ing our experimental system of in vitro PSNE as a model
of carcinoma initiation.
The PSNE signature is enriched in genes belonging to a
pathway of xenobiotic metabolism
In a second step, we searched for new pathways which
could be involved in the pre-malignant steps. To this
goal, the PSNE signature was analyzed according to
over-represented Gene Ontology (GO) terms within the
“molecular function” and “biological process” groups.
The top five of this ontology analysis is listed in Table 1.
The “molecular function” GO analysis revealed that the
most over-represented GO category is the oxidoreduc-
tase activity category (GO: 0016491) in which almost all
genes are up-regulated. The four other best statistically
over-represented categories comprise much less genes than
in the oxidoreductase activity category. These are the phos-
phoric diester hydrolase activity category (GO: 0008081),
the transaminase activity category (GO: 0008483), the neu-
tral amino-acid transporter activity category (GO: 0015175)
and the unfolded protein binding category (GO: 0051082)
(Table 1 and Additional file 2: Table S1). The “biological
process” GO analysis emphasized numerous genes involved
in response to stress, and to a less extent response to chem-
ical stimulus, external stimulus, cellular ketone metabolism
and epidermis development (Table 1). Next, the PSNE sig-
nature was analyzed by functional annotation using the
Kyoto Encyclopedia of Genes and Genome (KEGG), a com-
pendium of genes annotated and organized by signalling
pathway [20]. The most significant functional identified
pathway concerns the metabolism of xenobiotics by cyto-
chrome P450 (Table 2). It includes AKR1C3, AKR1C2,
GSTA4, ADH5, GSTP1, MGST2, ALDH3A1 that are all
up-regulated in E vs Y and E vs S. Interestingly, all these
genes belong to the GO oxidoreductase activity category
(Table 1 and group 3 in Additional file 2: Table S1) and
AKR1C2, AKR1C3 in particular, intersected with NMSC
pre-malignant gene sets (Figure 3C). The second most
significant identified pathway is that of aminoacyl-tRNA
biosynthesis including the IARS, WARS, AARS, GARS,
MARS genes that are all down-regulated in E vs Y and E
vs S (Table 2). The other pathways identified within the
top five KEGG pathways are Glycine, serine and threonine
metabolism, Glycolysis/Gluconeogenesis and Prion dis-
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Figure 2 Data mining strategy. Shown is a schematic diagram outlining our genomic bioinformatics analyses of the data generated by
microarray analysis and the following functional studies using pharmacological and genetic tools.
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IPA Canonical pathways. Three amongst the top five path-
ways that were highlighted by the analysis were the same as
those highlighted by the KEGG analysis, namely with the
best p value the Metabolism of xenobiotics by cytochrome
p450 including ADH5, AKR1C2, AKR1C3, MGST2,
GSTA4, CYP4B1, ALDH3A1 and GSTP1, in second Gly-
cine, serine and threonine metabolism and in the forth pos-
ition Aminoacyl-tRNA biosynthesis. The other two are
Interferon signaling and Aldosterone signaling in epithelial
cells (Table 3).
Taken together, these results suggest that genes encod-
ing proteins carrying oxidoreductase activity and involved
in the metabolism of xenobiotics may be crucial for the
early steps of transformation in the PSNE cellular model.
The oxidoreductase genes AKR1C2 and AKR1C3 promote
PSNE
We then investigated by genetics and pharmacological
approaches whether the AKR1C genes activated at sen-
escence in primary keratinocytes may function as onco-
genes, i.e. promote senescence evasion in the form of
pre-transformed cells. We first verified by RT-qPCR the
levels of AKR1C2, −C3 mRNAs in senescent NHEKs
and emerging cells compared with young NHEKs. From
Figure 3 Overlap between the PSNE gene signature and gene sets of cancer and premalignant related models. (A) Ingenuity Pathway
Analysis of the proportion of genes of the PSNE signature belonging to the Diseases and disorders category with a p value <0.0001. (B) Ingenuity
Pathway Analysis of the percentage of genes of the cancer category in A involved in common cancer types. (C) List of the genes from the PSNE
signature overlapping with data sets of pre-malignant non-melanoma skin pathologies from [14-19]. Were considered as overlapping only the
genes differentially regulated in the same direction in each set.
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RT-qPCR analyses performed with extracts from three
different donors, we observed an increase in AKR1C2,
−C3 levels at senescence followed by a much stronger
increase at emergence (Figure 4A), hence confirming the
microarray results. We next assessed whether the up-
regulated transcription of AKR1C2, −C3 genes resulted
in increased AKR1C2, −C3 protein levels. Western Blot
analysis revealed strongly increased protein levels at sen-
escence, further increased at emergence (Figure 4B).
To establish whether AKR1C2 and –C3 play a role in
PSNE, we examined whether decreasing their expression
at senescence could affect the emergence frequency. To
this goal, individual siRNAs directed against AKR1C2
or -C3 were transfected in senescent cells. As shown
in Figure 5A and B, AKR1Cs siRNA transfection of
senescent NHEKs resulted in strong decreased of
AKR1C2, −C3 at both mRNA and protein levels. We
first examined whether AKR1Cs siRNAs affected the
senescent state itself. The results show that four days
after transfection neither the population doubling num-
bers nor the percentage of SA-β-Gal positive cells were
affected (Additional file 1: Figures S3A and S3B). We
then monitored these siRNA-transfected senescent
NHEKs for the emergence frequency. For that, siRNA-
transfected senescent NHEKs were plated at low density,
and, once the emergence has occurred about 7 days after
transfection, the clones of emergent cells were manually
counted and the emergence frequency calculated as the
number of emergent clones on the number of initially
plated senescent cells. The results show that knocking-
down AKR1Cs diminished by a twofold factor the emer-
gence frequency (Figure 5C and 5D). We also examined
whether AKR1Cs could be involved in the proliferation
of the emergent NHEKs. For that, emergent NHEKs
were transfected with the siRNAs against AKR1C2
or –C3 or the control siRNAs and their proliferation
was followed during 7 days. The results show that
AKR1C2, −C3 knock-down inhibited proliferation of
emerging cells from four days after transfection (Figure 5E).
In contrast AKR1C2, −C3 silencing did not impact on
cell proliferation in young NHEKs (Figure 5E). Taken
together, these results indicate that AKR1Cs are in-
volved both in the process of emergence from senes-
cence and in the proliferation of the neo-formed
transformed cells.
We next wanted to determine whether AKR1C2, −C3
activity is required for post-senescence emergence. To
this goal, we treated senescent NHEKs with the AKR1C2
Table 1 Functional categorization of genes from the PSNE signature
Category Term P-value Count up % up Count down % down group
GO molecular function
GO:0008081 Phosphoric diester hydrolase activity 0.00207 5 1.74 2 0.69 1
GO:0051082 Unfolded protein binding 0.00225 5 1.74 3 1.04 2
GO:0016491 Oxidoreductase activity 0.00292 21 7.34 1 0.34 3
GO:0008483 Transaminase activity 0.0041 0 0 4 1.39 4
GO:0015175 Neutral amino acid transmembrane transporter activity 0.0042 0 0 4 1.39 5
GO biological process
GO:0042180 Cellular ketone metabolic process 2.02E-8 11 3.78 20 6.87 6
GO:0009605 Response to external stimulus 1.16E-6 24 8.24 13 4.46 7
GO:0008544 Epidermis development 2.44E-6 12 4.12 3 1.03 8
GO:0006950 Response to stress 6.51E-6 31 10.65 22 7.56 9
GO:0042221 Response to chemical stimulus 1.47E-5 28 9.62 15 5.15 10
The top five Gene Ontology terms within the “Molecular function” and the “Biological process” subcategories and associated p-values are listed. The number and
percentage of up- and down-regulated genes in each subcategory are indicated. A group number was attributed to each subcategory in order to spot the genes
belonging to each subcategory in Additional file 2: Table S1.
Table 2 KEGG functional annotation of genes from the PSNE signature
KEGG pathway P-value Genes
Hsa00980 : Metabolism of xenobiotics by cytochrome P450 0.0011 AKR1C3, AKR1C2, GSTA4, ADH5, GSTP1, MGST2, ALDH3A1
Hsa00970 : Aminoacyl-tRNA biosynthesis 0.0087 IARS, WARS, AARS, GARS, MARS
Hsa00260 : Glycine, serine and threonine metabolism 0.0234 CTH, SHMT2, PSAT1, CBS
Hsa00010 : Glycolysis/Gluconeogenesis 0.0315 LDHA, ADH5, BPGM, PCK2, ALDH3A1
Hsa05020 : Prion diseases 0.0322 IL1B, HSPA5, PRNP, IL1A
The top five over-represented molecular pathways of the PSNE signature using KEGG pathway analysis.
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inhibitor ursodeoxycholic acid [21] and AKR1C3 inhibi-
tor 3-(4-(Trifluoromethyl) phenylamino) benzoic acid
[22]. We first checked the efficacy of the inhibitors using
coumberone, a non-fluorescent probe reporter, which is
specifically metabolized by the AKR1C enzymes into fluor-
escent coumberol (see the methods section). We quantita-
tively measured coumberone metabolism in presence or
absence of ursodeoxycholic acid or 3-(4-(Trifluoromethyl)
phenylamino) benzoic acid in senescent NHEKs. We show
that addition of both AKR1C inhibitors decreased coum-
berone metabolism, validating the inhibitory effects of the
compounds (Figure 6A and B). We then determined the ef-
fects of AKR1C2, −C3 activity inhibition on senescence
and emergence as above. Population doublings and emer-
gence frequency were then determined as above. Both in-
hibitors did not affect senescence growth arrest, whatever
the concentration used (Additional file 1: Figures S4A
and B). Ursodeoxycholic acid significantly decreased the
emergence frequency at the same rate whatever the dose
(Figure 6C), while the AKR1C3 inhibitor was almost ineffi-
cient in impacting emergence (Figure 6D).
To further support a role of AKR1C2, −C3 in pre-
transformation, we investigated whether overexpressing
AKR1C2, C3 in senescent NHEKs could also increase
the emergence frequency. We used recombinant qdeno-
virus particles encoding V5-tagged AKR1C2, V5-tagged
AKR1C3, or, as control, GFP. The overexpression of
AKR1C2, −C3 were checked by western Blot using an
anti-V5, 48h after infection (Figure 7A). We next followed
the emergence frequency in AKR1C2, −C3 expressing
cells. We showed that AKR1C2 but not AKR1C3 overex-
pression increased significantly the emergence frequency
(Figure 7B).
In conclusion, these results indicate that the early steps
of transformation in the PSNE model, including emergence
from senescence and proliferation of the just emerged neo-
plastic cells are dependent, at least in part, on the expres-
sion and activity of AKR1C2 and to a less extent AKR1C3.
Discussion
Although it is widely believed that there is a stepwise pro-
gression from normal cells to squamous cell carcinoma,
the gene expression changes expected to induce the early
Table 3 IPA annotation of genes from the PSNE signature
Ingenuity canonical pathways P-value Genes
Metabolism of xenobiotics by cytochrome P450 0.000126 ADH5, AKR1C2, AKR1C3, MGST2, GSTA4, CYP4B1, ALDH3A1, GSTP1
Glycine, Serine and Threonine Metabolism 0.00138 PSAT1, CBS, GARS, CTH, PLCH2, PLCL1, SHMT2
Interferon signaling 0.000257 IFIT1, OAS1, MX1, IFNGR1, PSMB8
Aminoacyl-tRNA biosynthesis 0.000295 WARS, GARS, AARS, MARS, IARS
Aldosterone signaling in epithelial cells 0.001175 HSPA8, CRYAB, DNAJB4, HSPA9, PLCH2, DNAJA1, HSPA5, PLCL1, HSPB1
The top five over-represented molecular pathways of the PSNE signature using Ingenuity Pathway Analysis.
Figure 4 AKR1C2 and 3 expressions in senescence and post-
senescence emergence. (A) The mRNA levels of AKR1C2 and 3
were measured by RT-qPCR in extracts from young (Y), senescent (S)
and emergent (E) NHEKs obtained from three different donors.
AKRC2 and 3 mRNA levels were normalized to 18S levels (Student
t-test; *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001). (B) AKR1C2 and 3 protein
levels were evaluated by Western Blot in extracts from young (Y),
senescent (S) and emergent (E) NHEKs. The gel was equicharged
with extracts from an equal number of cells. The equicharged was
verified a posteriori by detecting the levels of GAPDH.
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oncogenic events that govern the early steps of malignant
transformation are almost completely unknown. Since
carcinomas always develop in a context of advanced age,
we performed in this study transcriptomic and bioinfor-
matics analyses to investigate the molecular events associ-
ated to the early steps of epithelial cell transformation
by using a primary keratinocyte model progressing to
senescence and giving rise to pre-neoplastic cells by a
mechanism of senescence evasion.
This model offers several advantages and is relevant to
the physiopathology of carcinogenesis for several reasons.
First, it deals with primary epithelial human cells display-
ing a normal caryotype. Second, it enables to compare
pre-transformed cells with the normal cells from which
Figure 5 Invalidation of AKR1C2 and 3 reduces preneoplastic transformation. Senescent NHEKs were subjected to AKR1C2 (si_1C2) and
AKR1C3 (si_1C3) silencing by siRNAs or to non-target siRNAs (si_Ctrl) for 4 days, or were not transfected (NT). (A) AKR1C2 and 3 mRNA levels were
analyzed by RT-qPCR and normalized to 18S levels (Student t-test; ***p≤ 0.001). (B) Protein extracts from an equal number of si_1C2, si_1C3 or
si_Crtl NHEKs were analyzed by immunoblotting with anti-AKR1C2 or anti-AKR1C3 antibodies. Quantification of immunoblots was performed
using Image J software, results are presented as the ratio AKR1C isoform/GAPDH. (C) The emergence frequency was determined by plating cells
at low density and monitoring the culture for the appearance of emergent clones. Once emergent clones have appeared (after 7days), the culture
dishes were stained by Crystal Violet and emergent clones were counted under microscopic observation. Countings were performed in triplicate
(Student t-test; *p < 0.05; **p < 0.01, by comparing the conditions si_Ctrl with si_1C2 or si_1C3). (D) Emergent clone as exemplified by phase-
contrast microphotograph. (E) Emergent or young cells were subjected to AKR1C2 (si_1C2) and AKR1C3 (si_1C3) silencing by siRNAs or to non-
target siRNAs (si_Ctrl) during 4 days, or were not transfected (NT). Cells were counted and cumulative doubling numbers were calculated. The
barplots represent the mean +/− s.d. of the counts of three independent culture dishes (Student t-test; *p < 0.05, of the comparisons of the con-
ditions si_Ctrl with si_1C2 or si_1C3). This experiment is representative of 3 independent ones.
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Figure 6 Inhibiting AKR1C2 and 3 activities reduces preneoplastic transformation. (A and B) Formation of fluorescent coumberol from
non-fluorescent coumberone (AKR1Cs substrate) in 96-well plate of senescent keratinocytes in presence of increasing concentrations of AKR1C2
inhibitor (ursodeoxycholic acid) or AKR1C3 inhibitor (3-(4-(Trifluoromethyl) phenylamino) benzoic acid). Results are shown as fold induction +/− s.d.
considering 100% the AKR1Cs activities obtained upon senescence. Each condition was performed in triplicate (Student t-test; *p≤ 0.05; **p≤ 0.01;
***p≤ 0.001). The results are representative of at least 3 independent experiments. (C and D) The emergence frequency was determined by plating
cells at low density and monitoring the culture for the appearance of emergent clones as in Figure 5D. Countings were performed in triplicate
(Student t-test; *p < 0.05, of the comparison of the untreated condition (0 μM) with treated conditions (0.03; 1; 3 μM)).
Figure 7 Overexpression of AKR1C isoforms 2 and 3 promotes preneoplastic transformation. (A) V5-tagged AKR1C isoforms 2 and 3
were overexpressed in senescent NHEKs from adenoviral vectors. Senescent NHEKs were infected with Ad-GFP, Ad-AKR1C2-V5 (Ad-C2-V5) or
Ad-AKR1C3-V5 (Ad-C3-V5) particles, and analyzed 48 h later by western blot using an-anti V5 antibody and an anti-GAPDH used as loading control.
(B) Once infected as in (A), the emergence frequency was determined as in Figure 5D. Countings were performed in triplicate (Student t-test;
*p < 0.05, of the comparison of the control-GFP condition with Ad-C2-V5/Ad-C3-V5 conditions).
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they directly originate, and not with neighbour normal
cells either of another type or which were submitted to
another environment as often the case when cells are mi-
crodissected off a tumor. Third, the comparison with nor-
mal cells can be done at two stages, when normal cells are
still actively proliferating but also, and more interestingly,
when they have reached the senescent stage. Since the
pre-transformed cells directly originate from a few senes-
cent cells [12], this enables to access to the transcriptomic
changes which occur at senescence and prepare to trans-
formation. In other words, the model can give access to a
mechanistic understanding of the pre-transformation
process by senescence evasion itself and not only to a de-
scription of the pre-transformed state once established.
Forth, the pre-transformation process is completely spon-
taneous, i.e. it is not dependent on a priming experimental
and sometimes artefactual event such as the introduction
of a known oncogene, or even worse on unknown genetic
modifications which have led to get an immortalized cell
line. Therefore it opens the possibility to discover totally
new pathways. And indeed, we found in the PSNE signa-
ture individual genes already annotated in cancer, in
pre-neoplastic skin lesions or in psoriasis, but no global
canonical pathway generally associated with cancer. For
instance, in the IPA pathway analysis, the first canonical
pathway generally associated with cancer that stands out
is “HER-2 signaling in cancer”; it stands out only at the
15th position. Similarly, in the KEGG analysis, the first ca-
nonical pathway relevant to cancer standing out is the
“p53 signalling pathway”, only at the 8th position.
An important consequence of the novelty of the model
is our discovery in the PSNE signature of the preponder-
ance of metabolic pathways. Amongst them, the “Metab-
olism of xenobiotics by cytochrome p450” is the one
highlighted with the best p value and with the higher
number of genes both by the IPA and KEGG analyses.
Several of the genes of this pathway are also found in
the oxidoreductase category of the IPA analysis. Remark-
ably, all these genes are up-regulated in the emergent
cells versus the young or the senescent ones. Moreover,
five on eight of these genes (AKR1C2, AKR1C3, GSTP1,
MGST2 and ALDH3A1) are target genes of the oxida-
tive stress-sensor NRF2 transcription factor. Since we
have previously shown that oxidative stress is necessary
and sufficient for both senescence and PSNE [12], this
suggests that these genes might be amongst the actors of
the process.
In order to assay this hypothesis, and more generally to
prove that the PSNE model and the strategy to generate
the PSNE signature has the potential to highlight path-
ways of importance in the process of pre-transformation
by senescence evasion, we genetically and pharmacologic-
ally manipulated some genes of the “Metabolism of xeno-
biotics by cytochrome P450” and examined whether this
could impact the process of emergence. Among the genes
of the pathway, we choose to invalidate AKR1C2 and
AKR1C3 because they were with CYP4B1 the most highly
up-regulated and because they are known to be physiolo-
gically expressed in the epidermis [23-25]. AKR1Cs are a
family of cytosolic NADP (H)-dependent oxidoreductases
involved in the metabolism of steroids (C1-C3), prosta-
glandins (C3), polyaromatic hydrocarbons (C1-C3) and
xenobiotics (C1, C2, C4,) [26-28]. Interestingly, the invali-
dation by RNA interference or the inhibition of AKR1Cs
enzymatic activity by specific pharmacological inhibitors
did not alter the senescent state itself, but significantly de-
creased the emergence frequency and the proliferation of
the emerged cells. Conversely, AKR1C2 overexpression
increased the frequency of PSNE, therefore validating the
PSNE signature as a signature of the process of neoplastic
emergence by senescence evasion in keratinocytes. How-
ever, in all genetic and pharmacologic manipulations of
AKR1Cs, AKR1C2 revealed to be more efficient than
AKR1C3 in promoting post-senescence evasion, probably
because of differences in activity or substrate specificity.
Therefore, although the overall PSNE signature can be
considered as relevant of the very first stages of transform-
ation, the exact implication of each gene must be experi-
mentally assayed.
Conclusions
Our results clearly indicate that the PSNE signature con-
tains numerous informations which should be helpful in
understanding basic molecular mechanisms involved in
the very initial steps of pre-neoplastic transformation re-
lated to age. Further studies should focus on how the ac-
tivity of the enzymes of the metabolism of xenobiotics
by cytochrome P450 modifies the physiology of senes-
cent keratinocytes to render them able to re-enter into
mitosis to generate pre-transformed cells. Moreover, our
findings suggest that a pharmacological intervention
may prevent or delay early steps of neoplastic transform-
ation. This may provide a foundation for future anti-
aging and anti-cancer therapeutic approaches.
Methods
Reagents and cell culture
Normal human epidermal keratinocytes (NHEKs) were
purchased from Clonetics (CC-2501) and Promocell. We
used cells from 3 different donors of different race and
age (referred as 4F0315, 2F1958, and K1MC). Cells were
obtained anonymously and informed consent of each
skin donor was obtained by the supplier. Cells were
grown at 37°C in an atmosphere of 5% CO2 in a KGM-2
BulletKit medium consisting of modified MCBD153 with
0,15 mmol/L calcium, supplemented with bovine pituitary
extract, epidermal growth factor, insulin, hydrocortisone,
transferrin, and epinephrin (Clonetics). Such a serum-free
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low-calcium medium was shown to minimize keratinocyte
terminal differentiation [29]. In all experiments, cells
were seeded at 3500 cells/cm2 and always splitted at
70% confluence. The number of population doublings
(PD) was calculated at each passage by means of the
following equation: PD = log (number of collected cells/
number of plated cells)/log2. Ursodeoxycholic acid and
3-(4-(Trifluoromethyl) phenylamino) benzoic acid were
obtained from Sigma and Calbiochem, and diluted in
ethanol and DMSO respectively.
Emergence efficiency
After siRNA transfection, adenoviral infection or chem-
ical treatment, senescent NHEKs were seeded into 10
cm dishes at the limit density for emergence (10,000
cells per dish). A few days later, the dishes were fixed
and stained by crystal violet, the emergent clones were
counted and the emergence frequency was calculated as
the ratio of the number of clones on the number of
seeded senescent cells [12].
Transcriptomics analysis
cDNA preparation
Total RNAs were extracted using RNeasy mini-columns
(QIAGEN). Double Stranded (DS) cDNA was synthe-
sised from total RNA using a SMART protocol [30].
Two first strand reactions were set up starting with
500 ng of total RNA. Four microliters of each first strand
reaction was used in the amplification step which was
performed using 17 rounds of cycling. The DS cDNA was
checked on a 1.2% agarose gel before the samples were
purified using Qiagen Qiaquick clean up columns. The
amount of cDNA amplified was then checked using the
Nanodrop ND1000.
cDNA labelling and microarray hybridisation
Using the Bioprime labelling kits (Invitrogen), 10μl of
purified cDNA was labelled, where 2 μl of Cye dye (GE)
was incorporated. After incubating for 3 hrs at 37°C, the
labels were purified using ProbeQuant G50 micro col-
umns (GE). Incorporation rates were determined using a
Nanodrop ND1000 before specific labels were pooled
and dried down to completion. The labels were resus-
pended in 40 μl of hybridisation buffer (40% deionised
formamide; 5× Denhart’s; 5× SSC; 1mM Na pyrophos-
phate; 50 mM Tris pH 7.4; 0.1% SDS) and hybridised
onto a RNG-MRC human set 25K microarray printed
on GE Codelink slide (http://www.mgu.har.mrc.ac.uk/
facilities/microarray/rng.html), overnight at 48°C in a water
bath using the Corning hybridisation chambers. After
hybridisation, the arrays were then washed initially in
2 x SSC until the coverslip had come off, then 5 min
with vigorous shaking in 0.1× SSC; 0.1% SDS and then
finally in 0.1 x SSC for 2 min with vigorous shaking.
The arrays were then spun dry and scanned using a
ProScanArray HT (Perkin Elmer, Beaconsfield, UK) and
the acquired images were analyzed using ImaGene 6.0.1
software (Bio Discovery, El Segundo, CA, USA). Three
biological replicates were used for each of the young
(Y), senescent (S), emergent (E) conditions. Dye-swap
hybridizations were performed with the samples la-
belled reciprocally (Cy5 vs Cy3) to eliminate the influ-
ence of dye bias for a total of 9 arrays.
Analysis of microarray
Raw Data were processed into R/Bioconductor (http://
www.bioconductor.org). Intensities were log2 trans-
formed and normalized using the Loess method [31].
The fitted values for each sample were then converted
back to red and green intensities. Moderated t-tests were
performed using the limma package [32] to compare the
following conditions: E vs Y and E vs S. Raw p-values
were adjusted for multiple testing with the Benjamini
Hochberg method. A false discovery rate (FDR) of 0.1%
[33] and Log2 (Fold change) cutoff ≥ 1.1 was applied to
the dataset for each condition [34]. We determined the
common set of differentially expressed genes shared be-
tween E vs Y and E vs S as the PSNE signature. Expres-
sion data sets containing gene identifiers (Entrez gene
identifiers) were uploaded and each gene identifier was
mapped to its corresponding gene object in the Ingenu-
ity Pathways Knowledge Base. The list of up- and down-
regulated genes was analyzed using Ingenuity Pathway
Analysis software 9.0 (www.ingenuity.com), and catego-
rized according to their Gene Ontology (using DAVID,
www.david.abcc.ncifcrf.gov/).
RNA isolation, reverse transcription and quantitative
real-time PCRs (qRT-PCR)
Total RNAs were extracted using RNeasy mini-columns
(QIAGEN). One μg of RNA was reverse-transcribed using
random hexamers, Superscript III and dNTPs (Invitrogen)
in a final volume of 20 μl according to manufacturer’s
instructions. Quantitative real-time PCR reactions were
performed using the Mx3005P Real-time PCR system
(Stratagen). Primers used were designed with qPrimerDe-
pot (http://primerdepot.nci.nih.gov/) and are listed in
Additional file 3: Table S2. PCR products were measured
by SYBR Green fluorescence (SYBR Green Master Mix,
Applied Biosystems). Experiments were performed in trip-
licates for each data point. Results were analyzed with the
MxPro software (Agilent). The expression of each gene
was normalized to 18S gene, and fold expression relative
to the control is shown.
Small interference RNA
Invalidation experiments for AKR1C2 and AKR1C3 were
performed using pools of siRNAs from Dharmacon (ON
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TARGET Plus Smart pool, Dharmacon, USA). A non-
targeting siRNA pool (Dharmacon) was used as control.
Young, Senescent or Emergent NHEKs were plated at
70,000 cells per well in six-well plates and were trans-
fected by using the RNAiMAX Lipofectamine reagent
(Invitrogen Corp., Carlsbad, CA, USA) or by using Pri-
meFect siRNA Transfection Reagent (Lonza) according
to manufacturer’s instructions.
Western-blotting
Equal numbers of young, senescent or emergent NHEKs
were lysed in Laemmli buffer 2× containing SDS 4%,
Glycerol 20%, Tris–HCl 50 mM pH 6.8, bromophenol
blue 0.02% and 2-Mercaptoethanol 5%. Samples were
denatured by heating at 95°C for 5 min. Proteins were
resolved by SDS-PAGE and transferred to nitrocellulose
membranes (Hybond-C extra, Amersham). Primary anti-
bodies used against AKR1C2 and AKR1C3 were from
Abcam and anti-human GAPDH mouse monoclonal
antibody was from Chemicon International, anti-V5 was
from Life Technologies. Secondary antibodies used were
peroxidase-conjugated (Jackson ImmunoResearch La-
boratories). Peroxidase activity was revealed using ECL
(enhanced chemiluminescence) or ECL advanced kit
(Amersham Biosciences).
Adenoviral infection
Adenoviral particles expressing AKR1C2-V5 (#SL170932)
or AKR1C3-V5 (#SL177696) were purchased from Signa-
Gen (Gaithersburg, MD, USA). AdGFP construction was
previously described [35]. In all experiments, cells were in-
fected at an input of 50 viral infectious particles/cells by
adding virus stocks directly in the culture medium. Four
hours later, the medium was replaced by fresh medium.
AKR1C enzyme activity assay
The enzyme activity of AKR1C was assayed according to
the procedure described by Halim et al. [36], with slight
modifications. Briefly, cells were added to 96-well plates
at a density of 6000 cells/well in phenol red-free media.
Concentrations of inhibitors (as indicated) were added to
the plate and incubated for 1 h, prior to addition of coum-
berone at concentration of 10 μM. Final volumes were
200 μl/well. The plates were returned to the incubator and
fluorescence intensity was read 7 h after coumberone
addition with excitation at 385 nm and emission at 510
nm on a FluoStar Optima platereader (BMG Labtech,
Cary, NC). Results were expressed as a percentage +/− s.d.
and normalized to control.
Statistical analyses
Student’s one- or two-tailed t tests, as appropriate, were
used for statistical analyses. The p values are indicated in
the diagrams with * for p values < 0.05, ** for p values <0.01
or *** for p values <0.001.
Ethics statement
Human cells used in this study provide from people
whose informed consent was obtained by the cell sup-
pliers (Clonetics, Promocell). Cells were obtained an-
onymously. No ethics approval was necessary for the
experiments performed therein.
Additional files
Additional file 1: Figure S1. Quality assessment of the microarray data.
(A) MAPlots of log-ratio of two expression intensities versus the mean
log-expression of the two upon loess normalization in the different
conditions (E vs Y; E vs S). (B) Histograms of raw p-values representing
the number of p-values that falls within different intervals. Figure S2.
Validation of the microarray data by quantitative real-time PCR. The
mRNA level of a random subset of genes were measured by qRT-PCR
and normalized to 18S levels. The barplots represent the mean +/- s.d. of
three independent experiments. Figure S3. AKR1C2 and 3 expressions
do not alter the senescent state. Senescent NHEKs were subjected to
AKR1C2 (si_1C2) and AKR1C3 (si_1C3) silencing by siRNAs or to non-
target siRNAs (si_Ctrl) for 4 days, or were not transfected (NT). (A) SA-b-
Gal-positive cells were counted in 3 different microscopic fields. The bar-
plots represent the mean +/- s.d. of the 3 counts. (B) Cells were counted
and cumulative doubling numbers were calculated. The barplots repre-
sent the mean +/- s.d. of the counts of three independent culture dishes.
Figure S4. AKR1Cs inhibitors do not alter senescence growth arrest. (A
and B) Senescent NHEKs were treated with ursodeoxycholic
acid or 3-(4-2 (Trifluoromethyl) phenylamino) benzoic acid. After four
days, cells were counted and cumulative doubling numbers were
calculated. The barplots represent the mean +/- s.d. of the counts of
three independent culture dishes.
Additional file 2: Table S1. The PSNE signature. List of the 286 genes
of the PSNE signature. The 145 genes belonging to the cancer category
in Figure 3A are highlighted in grey. The lane Group indicates the group
numbers corresponding to the functional subcategories listed in Table 1
to which each gene belongs.
Additional file 3: Table S2. List of primers for qRT-PCR.
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